MMR 2035FR

Salesforce, Inc. (CRM): analysis and signal as of September 7, 2026

Exchange : NYSE · Sector : Technology Services

In short

The signal on Salesforce remains moderate, with a unanimous vote of 3 out of 3. The thesis relies on operational quality and a supportive macroeconomic environment, but the recent increase and limited room for appreciation restrain momentum.

Current signal
moderate (vote 3/3)
Deterministic score
+2.0 → signal expected by the scale : moderate (September 10, 2026)
Layers
fundamentals : positive, price : positive, risks : neutral

Triggered rules

RuleWeight
favors robust fundamental health (high Piotroski F-Score)+1.5
penalizes direct holding of US securities in a CTO (US estate tax at death), favors a UCITS ETF domiciled in IE-1.0
favors a "fast grower" profile, high and durable earnings growth (> 20 %), to be cross-checked against the PEG+1.0
moderately favors an asset with robust operating profitability (RMW factor), cross-check with accounting quality (possible manipulation)+0.5

Thesis

Salesforce presents solid operational quality, illustrated by remaining performance obligations of 33,6 milliards USD, up 14 %, free cash flow of 3,42 milliards USD, also up 14 %, and a forward PER of 14,4x, below that of peers in the artificial intelligence sector. The expansionary macroeconomic regime, characterized by a bullish weighting of 0,58, supports demand for software and AI solutions. However, the 40 % increase over one month, limited room for appreciation of 4,5 % relative to consensus, and a complacent regime in derivatives markets expose the shares to an amplified decline in the event of adverse market direction.

Bull case

The remaining performance obligations of 33,6 milliards USD, growing 14 %, free cash flow of 3,42 milliards USD, up 14 %, and the forward PER of 14,4x, below that of Microsoft and Oracle, confirm the quality of the financial profile. The 25 milliards USD share repurchase program, the largest in the company's history, supports earnings per share. The expansionary macroeconomic regime, with a bullish weighting of 0,58, favors software and AI stocks.

Bear case

The 40 % increase in one month, including 25 % in a single week, reflects a surge in the share price that reduces the room for appreciation against consensus of 265,75 dollars, or 4,5 %. The complacent regime observed in derivatives markets, with VIX9D at 11,97 versus VIX3M at 17,61, representing a slope of -32 %, and a put/call ratio of 0,76, indicates limited hedging against downside risk. US inflation at 3,5 %, above target, and a positive 10-2 year yield curve slope of +0,41 point weigh on growth multiples. Short interest has increased by 5,8 % over 30 days to reach 1,59 % of the free float.

Scenarios

Bullish scenario: confirmation of the catalyst related to the next quarterly guidance, with continued growth in remaining performance obligations and free cash flow. Central scenario: consolidation of the share price within a narrow range after the 40 % increase over one month, pending a pullback toward an intermediate technical area. Bearish scenario: amplification of the decline in the event of a break below a medium-term technical reference, with limited hedging and the negative volatility slope intensifying the move.

Risks

The main risk lies in the sensitivity of the shares to a change in the macroeconomic regime or persistent inflation that would compress growth multiples. The concentration of the AI sector within indices amplifies volatility in the event of a sector rotation. A break below the 200-session moving average would invalidate the bullish thesis. The increase in short interest and the negative volatility slope indicate insufficient hedging against an exogenous shock.

Market positioning (short sellers)

Short interest / shares outstanding
3.32 %
Days to cover
2.33
Settlement date
2026-08-14
Source
FINRA (disseminated on 2026-08-26)

Market information published by FINRA (consolidated short interest, all venues), no directional comment.

Upcoming catalysts

DateDescription
T3 FY2027 results expected early December, indicative date

Signal history (last 12 months)

DateSignalNew fact
moderate (3/3)unchanged
moderate (2/3)unchanged (no prior verdict in memory, first analysis on this security). Personal analysis, not advice.

Frequently asked questions

What does Salesforce's RPO measure, and why is it important?

RPO, or remaining performance obligations, represents the total amount of contracted revenue that has not yet been recognized. It stands at 33,6 milliards USD, up 14 %, providing good visibility over future revenue and reflecting Salesforce's commercial quality.

What does the complacent regime observed in derivatives markets indicate?

The complacent regime is characterized by VIX9D at 11,97, below VIX3M at 17,61, representing a slope of -32 %, and by a put/call ratio of 0,76. This configuration indicates limited hedging against risks and increases vulnerability to an amplified decline.

What is the impact of the 25 milliards USD repurchase program?

The 25 milliards USD repurchase program, the largest in Salesforce's history, supports earnings per share and demonstrates management's confidence in the generation of free cash flow, which stands at 3,42 milliards USD, up 14 %.

Sources

The official filings below are the issuer's own, matched to this stock by its identifier (LEI, CIK or ISIN). The figures quoted above come from an automated arbitration: they have not been re-checked one by one.

Automated AI analysis: limitations and transparency

  • This content is an automated analysis produced using artificial intelligence. Personal analysis for information purposes — no personalised investment advice. MMR content consists of general research. It does not take account of your financial circumstances, objectives or risk tolerance. Data, analyses and results, including those produced using artificial intelligence, may contain errors, be incomplete or become outdated. No return or outcome is guaranteed. All investments carry a risk of partial or total loss of capital. Past performance and simulations do not predict future results. Before making any decision, check information against original sources and, where necessary, consult an authorised professional. You remain responsible for your investment decisions. This notice does not exclude or limit any liability that cannot legally be excluded or limited.
  • Tool and analysis: QDNA, Aurélien Ambert.
  • Analysis (arbitration) completed on September 7, 2026; this page was completed on September 7, 2026 at 07:13 (UTC).
  • Interests: no position in the stock analysed (CRM) is recorded in the data consulted on (UTC). This does not confirm the absence of holdings or other interests. The situation at the analysis publication date has not been reconstructed.
  • This declaration covers only recorded positions in this stock; it is not an exhaustive verification of other interests or remuneration.
  • Methodology: analysis chain, score formula and scale described on the public methodology page.
  • Analysis horizon: 2035.

See also